Study guide

3.2 Epidemiology and Inherent Risk Factors

ARRT Mammography Postprimary

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Postprimary Eligibility, Structured Education, and Clinical Requirements 1.3 Scoring, Retakes, Fees, and Credential Maintenance 1.4 2025 Content Outline, Domain Weights, and Study Strategy

2 Patient Communication

2.1 Pre-Exam Instructions 2.2 Explaining the Exam, Rapport, and Support 2.3 Patient Education: ACS/ACR Guidelines, BSE, CBE, Dose, and Modalities

3 Results Communication and Breast Cancer Risk

3.1 Process for Receiving Results and Additional Imaging 3.2 Epidemiology and Inherent Risk Factors 3.3 Social Risk Factors, Access, and Hormone Use 3.4 Signs and Symptoms of Breast Disease

4 History, Priors, and Treatment Context

4.1 Medical History, Physical Findings, and Gender Affirmation 4.2 Previous Mammograms 4.3 Surgical, Nonsurgical, and Reconstruction Options

5 Mammography Unit Design

5.1 kVp Range, Tube, Filtration, Window, and Focal Spot 5.2 Compression Paddles, Grids, and System Geometry

6 Digital Acquisition, Display, and Informatics

6.1 FFDM-DR/2D, DBT/3D, and Synthesized Imaging 6.2 Image Receptors and Acquisition vs Interpretation Monitors 6.3 HIS/RIS/EMR, PACS, and CAD

7 Accreditation, MQSA, EQUIP, and Density Reporting

7.1 Accreditation Bodies, FDA/MQSA Personnel, Records, Audits, and Policies 7.2 EQUIP: QA Oversight, Clinical Image Quality, and Corrective Action 7.3 Breast Density Reporting Requirements

8 Quality Control Testing

8.1 Mammographer QC: Phantom Image, Compression Thickness, Visual Checklist 8.2 Mammographer QC: Monitors, Repeat Analysis, Viewing Conditions, Compression Force, Detector Calibration 8.3 Physicist Tests: MEE, Collimation, Spatial Resolution/MTF, SNR/CNR, AEC, AGD, kVp, HVL 8.4 Physicist Tests: Artifacts, Phantom Quality, Illuminance, Tech QC Program Review, Compression Application/Paddle Alignment, Workstation QC

9 Technique and Image Evaluation

9.1 Technical Factors: kVp, mAs, AEC vs Manual, Target/Filter, Focal Spot, Grid, Mag, Labeling 9.2 EQUIP Image-Quality Criteria 9.3 Patient-Related Artifacts

10 Localization and Anatomy

10.1 Clock Position, Quadrants, and Triangulation 10.2 External Anatomy 10.3 Internal Anatomy: Fascia, Glandular Tissue, and the TDLU 10.4 Cooper Ligaments, Pectoral Muscle, Vascular/Lymphatic Systems, and Cytology

11 BI-RADS Lexicon

11.1 Architectural Distortion, Asymmetry, and Mass Features 11.2 Calcification Morphology and Distribution 11.3 Assessment Categories, Breast Density, and Recommendations

12 Breast Pathology

12.1 Benign Pathology and Mammographic Appearance 12.2 Lesions with Upgrade Potential 12.3 DCIS, IDC, and Invasive Lobular Carcinoma 12.4 Inflammatory Carcinoma, Paget Disease, Sarcoma, Lymphoma, and Metastases

13 Standard Screening Views

13.1 Craniocaudal (CC) Positioning 13.2 Mediolateral Oblique (MLO) Positioning

14 Additional Views I

14.1 Mediolateral (ML) and Lateromedial (LM) 14.2 XCCL, XCCM, Cleavage (CV), and Axillary Tail (AT) 14.3 Tangential (TAN) and Rolled Views (RL, RM, RS, RI)

15 Additional Views II

15.1 Implant Displaced (ID), Nipple in Profile, and Anterior Compression 15.2 Spot Compression and Magnification

16 Patient Variance

16.1 Chest Wall Variations, Kyphosis/Lordosis, Protruding Abdomen, and Extreme Breast Size 16.2 Irradiated Breast, Reduction Mammoplasty, and Postsurgical Breast 16.3 Male Patients and Lactating Breast 16.4 Breast Augmentation and Implanted Devices

17 Imaging Examinations

17.1 Screening vs Diagnostic Mammography 17.2 Breast Ultrasound and Breast MRI

18 Interventional Procedures

18.1 History, Consent, Time-Out, Setup, and Postprocedure Instructions 18.2 Stereotactic and Ultrasound-Guided Biopsy 18.3 Needle Localization, Specimen Imaging, and Clip Placement 18.4 Handling and Disposing of Biohazardous Materials

3.2 Epidemiology and Inherent Risk Factors

Key Takeaways Explain This Topic AI

ACS Cancer Facts & Figures 2026 estimates about 321,910 new invasive female breast cancers in the United States in 2026, about 32% of new cancers in women; breast cancer is the most commonly diagnosed cancer among U.S. women after skin cancers.

Inherent risk on the 2025 blueprint includes female sex assigned at birth and related reproductive timing, age, personal history of breast, ovarian, or lung cancer, genetic risk and family history, previous chest radiation, and breast tissue density.

Breast density both masks masses on mammography and is an independent risk factor; that dual role is why density belongs in both Image Production and this Patient Care chapter.

High-risk history (BRCA and related mutations, chest radiation at a young age, personal breast cancer) changes whether the exam is screening or diagnostic and whether supplemental imaging is likely — the mammographer documents; the clinician orders.

Last updated: August 2026

3.2 Epidemiology and Inherent Risk Factors

The 2025 ARRT Mammography blueprint expanded inherent risk factors under Patient Care. The exam wants more than a memorized list. It wants you to know why each item belongs on the history form and how it changes imaging: screening versus diagnostic, comparison with priors, positioning after surgery, and whether the radiologist is likely to discuss supplemental tests.

How common is breast cancer? Use a cited figure

Do not invent a 2026 “X percent of women this year” statistic. Cite a current official source.

The American Cancer Society’s Cancer Facts & Figures 2026 (the same projections NCI SEER displays as 2026 estimates) reports approximately 321,910 new invasive breast cancers in U.S. women , about 2,670 invasive cases in men, and about 60,730 additional cases of ductal carcinoma in situ (DCIS) in women. ACS estimates about 42,140 female breast cancer deaths in 2026 (about 42,670 deaths counting men). Among women, breast cancer accounts for about 32% of new cancer diagnoses in that ACS table — the leading site of new cancers in women when non-melanoma skin cancers are set aside.

ACS and NCI also still describe a lifetime risk on the order of about 1 in 8 U.S. women developing invasive breast cancer. That is a lifetime cumulative figure, not this year’s incidence rate. For the exam, the operational message is simpler: breast cancer is common , so screening volume is high, callbacks are a normal part of population screening, and a “low risk” history never means “skip the history.”

Incidence rises with age . Most invasive diagnoses occur in older adults, which is why age is the dominant population-level inherent factor even though young patients can have aggressive disease. ACS has also reported that incidence has been rising, including a somewhat steeper recent increase in women younger than 50, which is one reason a 42-year-old on your schedule is not “too young to take seriously.”

Inherent factors the blueprint expects you to collect

ARRT groups several items as inherent — they are largely not chosen the way alcohol or hormone prescriptions are. Female sex assigned at birth is the strongest demographic risk compared with male breast tissue, because of breast epithelial volume and lifetime estrogen-progesterone cycling. Within that group, longer estrogen exposure raises risk: early menarche , late menopause , nulliparity (never having a full-term pregnancy), and late primiparity (first full-term pregnancy at an older age, often taught around 30 years or later). Pregnancy and lactation interrupt cycling; a late first birth means more years of uninterrupted stimulation before that interruption. You are not calculating a Gail score at the console. You are recording menstrual and pregnancy history so the interpreting physician and referring clinician have it, and so you do not treat a nulliparous 35-year-old with a lump as “unlikely.”

Age belongs on every ticket. It drives screening start and stop decisions at the referring-provider level (USPSTF, ACS, and ACR do not all use the same start age — do not pick a fight with the order; protocol the exam that was ordered and document age accurately). Age also correlates with fatty replacement in many patients, which can make mammography more sensitive — the opposite of dense tissue in younger patients — but age never lets you skip a reported symptom.

Personal history of cancer on the 2025 outline specifically includes breast, ovarian, and lung . Personal breast cancer changes everything: the examination may be diagnostic rather than screening if there is a new clinical concern; lumpectomy, mastectomy, reconstruction, and radiation change positioning, landmarks, and which views are possible; the contralateral breast remains at elevated risk for a new primary. Ovarian cancer in the patient’s own history is a hereditary-syndrome flag (BRCA pathway) even if the breasts “feel fine.” Lung cancer belongs on the form because metastatic disease to the breast or axilla, prior chest radiation or surgery, and a new breast finding in a patient with a recent lung primary are protocol questions, not trivia.

Genetic risk includes family history and known mutations . First-degree relatives (parent, sibling, child) with breast cancer, especially premenopausal, bilateral, or male breast cancer, and family ovarian cancer, raise suspicion for hereditary syndromes. BRCA1 and BRCA2 are the names the exam expects; other high- or moderate-penetrance genes (for example PALB2, TP53, PTEN, CDH1, CHEK2, ATM) also appear in real clinics. You do not need to recite lifetime-risk percentages from memory if you cannot cite the current gene-specific figure. You do need to know that a documented mutation or a striking family history often means earlier screening , shorter intervals , and MRI or other supplemental imaging ordered by the clinician . Your job is to capture the history, including male relatives, and not to dismiss a 28-year-old BRCA carrier as “not due for mammography” if a diagnostic or high-risk order is sitting in the worklist.

Previous chest radiation , especially therapeutic radiation in adolescence or young adulthood (the classic example is mantle-field treatment for Hodgkin lymphoma), is a high-risk inherent factor. Those patients may start mammography years earlier than average-risk peers and often have MRI as well. Skin and tissue can be less elastic; document the history so positioning and comparison make sense.

Breast tissue density (composition) is both an inherent factor and a results-communication issue. Density is the relative amount of fibroglandular tissue versus fat. It is not the same as a palpable “firmness” the patient reports, and it is not something you assign from compression thickness. The radiologist classifies it. Dense tissue does two separate things: it masks masses because both tumor and fibroglandular tissue are radiopaque, and it is an independent risk factor for developing breast cancer. That is why the federal lay letter says dense tissue makes cancer harder to find and raises risk. Heterogeneously dense and extremely dense categories are “dense” for the patient letter; fatty and scattered are “not dense.” Supplemental screening (ultrasound, MRI, contrast mammography) is a clinician–patient decision after that letter, not a technologist add-on.

Factor to imaging implication

Inherent factor Why it matters biologically What you do in the breast center

Female sex assigned at birth; early menarche, late menopause, nulliparity, late first birth Longer cumulative estrogen-progesterone exposure of breast epithelium Record menstrual and pregnancy history; do not down-triage symptoms because the patient is young or has “no kids”

Age Incidence rises with age; most invasive cases are in older adults Record exact age; protocol the ordered exam; still convert to diagnostic for a new lump at any age

Personal breast, ovarian, or lung cancer Recurrence, contralateral primary, hereditary overlap, metastasis, treatment changes Ask about surgery, radiation, reconstruction; many new concerns are diagnostic, not screening

Family history; BRCA and other mutations High-penetrance genes substantially raise lifetime risk Capture which relatives and ages; expect possible MRI or shorter-interval orders

Chest radiation at a young age Direct DNA injury to breast tissue High-risk protocols; gentle positioning; document age at treatment if known

Dense breast composition Masks masses and independently raises risk Density is assigned on the report and explained in the lay letter; extra imaging is ordered, not improvised

A workable memory hook: inherent risk tells you who may need a different protocol; symptoms tell you who must leave the screening stream today. The next sections cover social factors and those symptoms. Density is the item that sits in both columns — it is biology and it is a federally required sentence in the results letter.